Biosimilars - the Brexit of the pharmaceutical industry?
In this article, Senior Consultant Jenna Earl explains what factors influence the uptake of biosimilars in the UK, comparing them to the same principles that help us navigate the complexities of Britain exiting the EU (Brexit).
availability of biosimilars for nearly a decade, uptake in the UK is still
lagging behind other EU markets, leading to the recent formation of the British Biosimilars Association (BBA) - part of the British Generic Manufacturers Association (BGMA).
are undoubtedly a hot topic for providers of branded biologic medicines,
biosimilar suppliers themselves, and the payers, healthcare professionals and
patients involved in biologic treatment. Much like the EU referendum, they
feature regularly in the news - with spectators waiting anxiously, in some
cases eagerly, for a change that could alter the treatment landscape for
several significant therapy areas.
understand the factors influencing the uptake of biosimilars you could apply
the same principles as you would to navigating the complexities of Britain
exiting the EU (Brexit).
1. Control is in the
hands of the people
relationship with the EU will be decided by a referendum, placing the decision
in the hands of the people. In the UK, the decision to prescribe a biosimilar
is still largely down to the healthcare professional (HCP) but, if this were to change, impact on
biologic markets could be dramatic.Despite NICE recommending
biosimilars ahead of branded biologics in several disease areas, this does not
appear to be happening in clinical practice. The next step for governing bodies
to ensure biosimilars are prioritised in the treatment pathway is substitution,
replacing a branded biologic with its corresponding biosimilar at point of
dispensing; a move that would result in a huge uplift in biosimilar use.Arguably,
the reason this hasn’t happened yet is that the financial gain generated by
such a move does not yet outweigh the repercussions of reducing the role of the
HCP in such an important decision. But with increasing pressure on the NHS to
make cost savings and expect greater value from treatments, this could change
in the future.
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of the healthcare professional (HCP) in the patient journey? Associate Consultant Ditte Funding discusses challenges and opportunities. Blue Latitude Health
Although not without its challenges, the appropriate care and support available to patients with prostate cancer is gradually evolving. It’s important not to overlook the all too often ‘unsung heroes’ of prostate cancer; those who care for the patients. Associate Consultant Frances Peters takes a look at the issues and concerns facing the caregivers of those with prostate cancer. Blue Latitude Health
Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what this means for pharma strategists and their product lines. Blue Latitude Health
As companies work to find innovative marketing techniques to cut through the noise, influence mapping has seen an increase in popularity. Associate Consultant Pany Koizi talks through how to get the most out of the influence mapping process. Blue Latitude Health
Founded by Michael Seres in 2011, 11 Health is a connected medical device company currently working to change the lives of patients using stoma bags. Content Marketing Manager Liz Inskip interviews Michael about how patients are changing the role of the expert in healthcare, and the systematic barriers to innovation in healthcare. Blue Latitude Health
As a business that works with healthcare and pharma companies, it’s not often that we get the opportunity to design the cover for Time Out London, so we jumped at the chance to partner with Rays of Sunshine to help them get the word out about their #Kisses4Wishes campaign on Valentine’s Day. Liz Inskip talked with the creative team about the campaign and how BLH approaches this kind of work.
Blue Latitude Health